# MRT-2359 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/mrt-2359

> MRT-2359, sponsored by Monte Rosa Therapeutics, Inc. (GLUE): 4 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, exact day, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | MRT-2359 |
| Codes | MRT-2359 |
| Sponsor | Monte Rosa Therapeutics, Inc. (GLUE) https://sec-api.dev/companies/glue/catalysts |
| Indications | myc-driven solid tumors and initial data |
| Modality |  |
| FDA designations | fast track, orphan |

## Timeline

### Sep 2022: trial start

- Status: completed. Date confidence: month. Stage: 1/2.
- First seen 2025-03-20, last confirmed 2025-03-20.
- SEC Form 10-K (accession 0000950170-25-042344): "We received FDA clearance of our IND for MRT-2359 in September 2022 and initiated patient dosing in our ongoing Phase 1/2 clinical trial in October 2022." https://www.sec.gov/Archives/edgar/data/1826457/000095017025042344/glue-20241231.htm

### Q1 2025: interim data readout

- Status: scheduled. Date confidence: quarter. Stage: 1. Indication: MYC-driven solid tumors and initial data.
- First seen 2025-01-10, last confirmed 2025-01-10.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-003776): "Building on this tremendous momentum, we enter the new year excited to disclose additional Phase 1/2 clinical data for MRT-2359 in patients with MYC-driven solid tumors and initial data from our Phase 1 single and multiple ascending dose trial of MRT-6160, both of which are anticipated in the first quarter of 2025." https://www.sec.gov/Archives/edgar/data/1826457/000095017025003776/glue-ex99_1.htm

### December 16, 2025: interim data readout

- Status: completed, positive. Date confidence: exact. Stage: 1/2.
- First seen 2025-12-16, last confirmed 2026-03-17.
- SEC Form 8-K (accession 0001193125-25-319981): "On December 16, 2025, the Company announced positive interim data from its ongoing Phase 1/2 clinical study evaluating MRT-2359 in combination with enzalutamide in heavily pretreated patients with metastatic CRPC." https://www.sec.gov/Archives/edgar/data/1826457/000119312525319981/glue-20251216.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-319981): "BOSTON, Mass., Dec. 16, 2025 - Monte Rosa Therapeutics, Inc. Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced positive interim data from an ongoing Phase 1/2 clinical study evaluating MRT-2359 in combination with enzalutamide in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC)." https://www.sec.gov/Archives/edgar/data/1826457/000119312525319981/glue-ex99_1.htm
- SEC Form 10-K (accession 0001193125-26-109360): "In December 2025, we announced positive interim data from an ongoing Phase 1/2 clinical study evaluating MRT-2359 in combination with enzalutamide in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC)." https://www.sec.gov/Archives/edgar/data/1826457/000119312526109360/glue-20251231.htm

### 2026: trial start

- Status: scheduled. Date confidence: year. Stage: 2.
- First seen 2025-12-16, last confirmed 2026-05-07.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-210298): "The Company plans to initiate a Phase 2 study (MODeFIRe-1) in 2026 of up to 25 patients to efficiently assess the efficacy of MRT-2359 in combination with the second-generation AR inhibitor apalutamide in mCRPC patients with AR mutations, with potential to expand the study into additional patient subsets." https://www.sec.gov/Archives/edgar/data/1826457/000119312526210298/glue-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-109353): "The Company plans to initiate a Phase 2 study in 2026 of up to 25 patients to efficiently assess the efficacy of MRT-2359 in combination with the second-generation AR inhibitor apalutamide in mCRPC patients with AR mutations, with potential to expand the study into additional patient subsets." https://www.sec.gov/Archives/edgar/data/1826457/000119312526109353/glue-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-319981): "Company plans to initiate a new, signal-confirming Phase 2 study of MRT-2359 targeting AR mutant and AR signaling-dependent patients in 2026" https://www.sec.gov/Archives/edgar/data/1826457/000119312525319981/glue-ex99_1.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/mrt-2359.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "MRT-2359 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/mrt-2359

```bibtex
@misc{secapidev_pdufa_mrt_2359_20261116,
  title        = {MRT-2359 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/mrt-2359}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_mrt_2359_20261116","title":"MRT-2359 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/mrt-2359","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
